Segall Bryant & Hamill, LLC Dexcom Inc Transaction History

Segall Bryant & Hamill, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$112.47 - $130.98 $30,366 - $35,364	270 Added 3.76%	7,450 $957,000
Q1 2023 May 15, 2023	SELL	$104.0 - $122.92 $31,200 - $36,876	-300 Reduced 4.01%	7,180 $834,000
Q4 2022 Feb 14, 2023	SELL	$84.98 - $122.67 $25,494 - $36,801	-300 Reduced 3.86%	7,480 $847,000
Q3 2022 Nov 14, 2022	SELL	$76.35 - $94.18 $64,133 - $79,111	-840 Reduced 9.74%	7,780 $627,000
Q2 2022 Aug 15, 2022	BUY	$67.99 - $132.89 $436,835 - $853,818	6,425 Added 292.71%	8,620 $642,000
Q2 2021 Aug 12, 2021	SELL	$80.99 - $107.93 $2.01 Million - $2.68 Million	-24,832 Reduced 91.88%	2,195 $234,000
Q1 2021 May 13, 2021	BUY	$84.79 - $104.74 $2.11 Million - $2.6 Million	24,832 Added 1131.3%	27,027 $2.43 Million
Q4 2020 Feb 12, 2021	BUY	$78.0 - $104.5 $12,480 - $16,720	160 Added 7.86%	2,195 $202,000
Q3 2020 Nov 13, 2020	BUY	$95.51 - $112.95 $22,444 - $26,543	235 Added 13.06%	2,035 $209,000
Q4 2019 Feb 11, 2020	SELL	$36.62 - $57.29 $17,211 - $26,926	-470 Reduced 20.7%	1,800 $98,000
Q2 2019 Aug 14, 2019	BUY	$27.84 - $38.92 $63,196 - $88,348	2,270 New	2,270 $0

1,013

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $30.6B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.